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Abstract
Background:  Interleukin 4 (IL-4) has been shown to suppress interleukin-1 (IL-1) induced
expression of matrix metalloproteinase-3 (MMP-3) in human synovial and gingival fibroblasts, but
the mechanism of suppression has not been determined. Activators of peroxisome proliferator-
activated receptor-γ (PPARγ) have been shown to inhibit cytokine induced expression of MMPs in
other cell types, and IL-4 has been shown to activate PPARγ by stimulating production of ligands
through the lipoxygenase pathway. It has been suggested that PPARγ may inhibit expression of
MMPs by competing with transcription factor AP-1 for binding to a putative composite binding
element in the promoters. The objective of this study was to determine whether the suppressive
effects of IL-4 on the IL-1 induced expression of MMP-3 involve activation of lipoxygenase and/or
PPARγ.
Results: Western blotting revealed the presence of PPARγ in nuclear extract of HGF. IL-1 induced
binding of nuclear extract to the putative composite PPRE/AP-1 site was diminished in the presence
of pioglitazone, but there was no evidence of any change in the composition of the retarded
complexes, and no evidence of PPARγ binding to this site. Nordihydroguaiaretic acid (NDGA), a
non-selective lipoxygenase inhibitor, and MK886, a specific inhibitor of 5-lipoxygenase, induced
MMP-3 expression synergistically with IL-1. However IL-4 was still able to inhibit MMP-3
expression in the presence of NDGA or MK886 and IL-1. Activation of PPARγ with pioglitazone
not only failed to inhibit IL-1 induced expression of MMP-3 mRNA, but rather super-induced MMP-
3 in the presence of IL-1. PPARγ antagonist GW9662 failed to abolish the suppressive effects of IL-
4. Another PPARγ activator, 15-deoxy-Delta12,14prostaglandin J2 (15dPGJ2), also super-induced
MMP-3 mRNA, and this was due at least in part to increased transcription.
Conclusion:  IL-4 suppression of IL-1-induced MMP-3 expression in HGF is independent of
lipoxygenase activity and activation of PPARγ. Super-induction of MMP-3 by pioglitazone may have
important implications for patients using pioglitazone to treat type II diabetes in the presence of
chronic inflammation.
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Background
MMP-3 (stromelysin-1) is a metalloproteinase with broad
substrate specificity, degrading proteoglycan, laminin,
fibronectin, and the non-fibrillar collagens [1]. Perhaps
equally important, it is also capable of activating other
pro-MMP's, including MMP-1, -8, -9 and -13 [2-4], of
inactivating plasminogen activator inhibitor I [5], and of
cleaving E-cadherin [6] and FasL [7]. MMP-3 is produced
by gingival and synovial fibroblasts, chondrocytes, macro-
phages, neutrophils, and endothelial cells in response to
inflammatory cytokines and mitogens. In periodontitis,
MMP-3 is present at increased levels in active disease sites
compared to inactive or healthy sites [8-11], and the levels
are correlated with clinical parameters and associated with
progression of the disease [11]. A similar situation exists
in rheumatoid arthritis [12]. Studies of the effects of a pro-
moter polymorphism that affects protein expression has
shown that individuals with the high expressing 5A/5A
genotype are at increased risk for aneurysms and myocar-
dial infarctions [13-15], while those with the lower
expressing 6A/6A genotype show a faster progression of
atherosclerosis [15,16]. Taken together, these studies sug-
gest that regulation of MMP-3 levels is important for the
maintenance of health, and that either too much or too
little can have detrimental effects.
Chronic inflammation in rheumatoid arthritis and perio-
dontitis is characterized by increased levels of IL-1β, TNFα
and prostaglandin E2 (PGE2), which contribute to
destruction of joints and alveolar bone in part through
increased production of matrix metalloproteinases
(MMPs) [17-20]. In addition, there is a relative absence of
IL-4-producing T cells at sites of inflammation [12,21-25].
This imbalance is progressive, with decreasing levels of IL-
4 correlated with loss of collagen and with increasing clin-
ical severity [26]. In addition, polymorphisms in the IL-4
promoter and intron that are associated with decreased
serum levels of IL-4 are also associated with increased sus-
ceptibility to early onset periodontitis [27]. It has been
suggested that correcting this cytokine imbalance in
chronic inflammatory conditions might be therapeutic. In
fact, adenoviral transfer of IL-4 has been shown to be pro-
tective against cartilage degradation induced by injection
of rheumatoid arthritis synovial tissue into joints of SCID
mice [28] and against collagen-induced arthritis [29].
IL-4 has been shown to inhibit the IL-1 induction of
MMP-3 expression in human conjunctival fibroblasts
[30], skin fibroblasts [31] and articular chondrocytes
[32,33], as well as in synovial fibroblast cultures estab-
lished from patients with osteoarthritis [34] and gingival
fibroblast (HGF) cultures established from patients with
periodontitis [35]. The mechanism of the inhibition of
MMP-3 by IL-4 in HGF was not determined, although
PGE2 was not involved, and DNA binding of transcrip-
tion factors AP-1 and NF-κB to their consensus sequences
was not inhibited [35].
Peroxisome proliferator-activated receptor-γ (PPARγ) is a
member of the nuclear receptor super-family. It plays an
important role in adipogenesis and insulin sensitization
and has also been shown to have a number of anti-inflam-
matory effects [36]. IL-4 has been shown to activate PPARγ
in macrophages by increasing the activity of 15-lipoxyge-
nase, leading to increased production of ligands [37-39].
PPARγ ligands and agonists have been shown to inhibit
production of MMP-3 [40,41], and to prevent MMP-
mediated tissue destruction in animal models of inflam-
mation, including arthritis [42,43] and periodontitis [44].
A recent study by Francois, et al. [45] identified a compos-
ite element in the rabbit MMP-1 promoter that exhibited
mutually exclusive binding of PPARγ or AP-1 and was
responsible for reduced gene expression in the presence of
PPARγ agonist rosiglitazone in chondrocytes. The authors
reported that computer-based analysis of the human
MMP-1 and MMP-3 promoter sequences revealed similar
putative composite elements overlapping the well-studied
AP-1 sites in each gene. The present study was undertaken
to determine whether there is a functional composite
PPRE/AP-1 site in the MMP-3 promoter, and if so,
whether it is involved in IL-4 suppression of IL-1 induced
expression of MMP-3 in HGF. Results show that there is
no binding of PPARγ to this site in HGF, and that the sup-
pressive effects of IL-4 are independent of lipoxygenase
activity and PPARγ. Surprisingly, a 5-lipoxygenase inhibi-
tor and a PPARγ activator both super-induce MMP-3 in
the presence of IL-1.
Results
PPAR-γ is present in HGF nuclear extract
PPARγ is present in the cytosol until ligand binding, at
which point it forms heterodimers with retinoid X recep-
tor (RXR) and migrates to the nucleus. In order to demon-
strate the presence of PPARγ in HGF, nuclear extract were
isolated from control cultures and from HGF cultures
treated for 24 hours in the presence of IL-1 (10 ng/ml)
and/or IL-4 (10 ng/ml). Results (Figure 1) showed that
PPARγ is present in the nucleus of cytokine-stimulated
HGF.
Pioglitazone and IL-4 reduce AP-1 binding to the putative 
PPRE/AP-1 site, but do not change the composition of the 
complexes
Previous studies have shown that IL-4 inhibition of IL-1
induced expression of MMP-3 is not associated with any
alteration in AP-1 binding. However, those studies were
done with an AP-1 consensus probe or a probe containing
only the AP-1 site from the MMP-3 promoter, neither of
which would have encompassed the putative compositeBMC Molecular Biology 2007, 8:12 http://www.biomedcentral.com/1471-2199/8/12
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PPRE/AP-1 site proposed by Francois et al. [45]. In order
to determine whether the composite site is functional in
HGF, and whether it is involved in the ability of IL-4 to
suppress MMP-3 expression, gelshift assays were per-
formed using an oligonucleotide probe containing the
putative composite site. As shown in Figure 2A, IL-1
induced binding to this site was diminished slightly in the
presence of IL-4 or pioglitazone. However, neither piogli-
tazone nor IL-4 alone altered binding patterns compared
to control – there were no additional bands or alterations
in migration to suggest binding of alternative proteins.
PPARγ anti-sera failed to shift the complex, and the ability
of anti-sera directed against members of the AP-1 family
to super-shift the complex was unchanged in the presence
of IL-4 or pioglitazone (Figure 2B). In addition, an oligo-
nucleotide probe corresponding to the consensus PPAR
binding site failed to compete for binding to the PPRE/AP-
1 probe (data not shown).
Inhibition of lipoxygenase fails to inhibit MMP-3 
expression
In order to determine whether the ability of IL-4 to inhibit
IL-1 induced expression of MMP-3 was linked with its
ability to induce and/or activate lipoxygenase enzymes, a
non-specific lipoxygenase inhibitor, NDGA, was added to
the cultures. As shown in Figure 3A, addition of NDGA
did result in a dose dependent increase in MMP-3 mRNA
in the presence of IL-1 plus IL-4. However, NDGA alone
increased MMP-3 expression relative to control. NDGA
also resulted in a further induction of MMP-3 in the pres-
ence of IL-1. Importantly, IL-4 was still able to inhibit
MMP-3 expression induced by IL-1 plus NDGA. Previous
results [35] showed that IL-4 fails to inhibit IL-1 induced
expression of MMP-1 in HGF. Those results are confirmed
here (Figure 3B). IL-4 increased MMP-1 expression com-
pared to control, and there was no significant difference
between IL-1 alone and IL-1 plus IL-4. NDGA had no sig-
nificant effect in the presence of IL-1 and/or IL-4,
although it did increase the basal levels of MMP-1 simi-
larly to MMP-3.
Similar results were seen with a specific inhibitor of 5-
lipoxygenase, MK886, which also increased MMP-3 pro-
tein levels (Figure 4). Again, IL-4 was still able to inhibit
MMP-3 mRNA induced by IL-1 + MK886. The induction
appears to occur at least in part at the transcriptional level,
since MK886 increased transcription of an MMP-3 pro-
moter construct in transiently transfected COS cells (Fig-
ure 4C).
Activation of PPARγ with Pioglitazone or 15dPGJ2 does not 
inhibit IL-1 induced expression of MMP-3 mRNA in HGF
The fact that IL-4 could still inhibit MMP-3 expression in
the presence of NDGA suggested strongly that lipoxygen-
ase activation is not involved in the inhibition, and the
gelshift results demonstrate that there is no competition
between PPARγ and AP-1 for binding to the promoter.
However, it is possible that IL-4 could activate PPARγ
through increased production of alternative ligands [39],
and that activation of PPARγ might inhibit MMP-3 expres-
sion through another mechanism, such as competition
for transcriptional co-activators [46,47]. In order to deter-
mine whether activation of PPARγ leads to suppression of
MMP-3 expression in these cells, HGF cultures were pre-
treated with increasing doses of the selective PPARγ ago-
nist pioglitazone for one hour before addition of IL-1.
Total RNA was harvested six hours later and analyzed by
real-time PCR. Results of three independent experiments
(Figure 5) showed that pioglitazone was not able to
inhibit IL-1 induced expression of MMP-3. In fact, piogli-
tazone further increased MMP-3 mRNA in the presence of
IL-1 (p = 0.025 at 1 µM and p = 0.060 at 10 µM). Likewise,
another activator of PPARγ, 15dPGJ2 also seemed to
super-induce MMP-3 mRNA expression in the presence of
IL-1, although this did not reach statistical significance
(Figure 6A). In transiently transfected COS cells, however,
15dPGJ2 cause a small but significant induction of tran-
scription of an MMP-3 promoter construct (Figure 6B). In
accordance with these findings, the ability of IL-4 to
inhibit MMP-3 expression was not affected by the PPARγ
antagonist, GW9662 (Figure 7).
Discussion
Results shown here demonstrate that there is no competi-
tion between PPARγ and AP-1 for binding to the MMP-3
promoter, and that IL-4 suppression of IL-1-induced
expression of MMP-3 in HGF does not involve activation
of lipoxygenase enzymes and/or PPARγ. However, the fact
that inhibitors of lipoxygenase and an activator of PPARγ
both resulted in super-induction of MMP-3 in the pres-
ence of IL-1 suggests that these factors may play a role in
MMP-3 gene regulation.
PPARγ is present in HGF nuclear extract Figure 1
PPARγ is present in HGF nuclear extract. Fifteen µg 
nuclear extract isolated from untreated HGF and HGF 
treated for 24 hour with IL-1 (10 ng/ml), IL-4 (10 ng/ml), or 
IL-1 and IL-4 were separated on 10% SDS-PAGE, and trans-
ferred to nylon membrane. Proteins were detected with anti-
PPAR-γ antibodies followed by chemiluminescence. C = con-
trol, no cytokines.
       C    IL-1     IL-4   IL-1+4 
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There is no qualitative change in binding to the PPRE/AP-1 site in the presence of IL-4 or pioglitazone Figure 2
There is no qualitative change in binding to the PPRE/AP-1 site in the presence of IL-4 or pioglitazone. A) HGF 
were incubated in the presence of IL-1 (10 ng/ml), IL-4 (10 ng/ml), and/or pioglitazone (1 µM) as indicated for 1 hour. Five µg 
nuclear extract were incubated with a 32P-labeled oligodeoxynucleotide probe containing the putative composite PPRE/AP-1 
site from the MMP-3 promoter. P = probe alone, no extract; C = control, no cytokines. B) HFG were incubated in the pres-
ence of IL-1 (10 ng/ml) or IL-4 (10 ng/ml for 1 hour. Five µg nuclear extract were incubated with the PPRE/AP-1 site probe in 
the presence of the indicated antibodies. P = probe, no extract.
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IL-4 suppression of MMP-3 is independent of lipoxygenase activity, but inhibition of lipoxygenase super-induces MMP mRNA Figure 3
IL-4 suppression of MMP-3 is independent of lipoxygenase activity, but inhibition of lipoxygenase super-induces 
MMP mRNA. HGF cultures were pre-treated with NDGA at the indicated doses for 1 hour prior to addition of IL-1 (10 ng/
ml) and/or IL-4 (10 ng/ml). Total RNA was harvested 12 hours after cytokine treatment, quantitated by real-time PCR and nor-
malized to levels of GAPDH. A) MMP-3. The graph represents data from seven independent experiments performed in tripli-
cate, expressed as mean +/- SEM. B) MMP-1. The graph represents five independent experiments performed in triplicate, 
expressed as mean +/- SEM. Statistical significance was determined using Student's t-test.
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A specific inhibitor of 5-lipoxygenase, MK886, super-induces MMP-3 mRNA and protein Figure 4
A specific inhibitor of 5-lipoxygenase, MK886, super-induces MMP-3 mRNA and protein. HGF cultures were pre-
treated with NDGA at the indicated doses for 1 hour prior to addition of IL-1 (10 ng/ml) and/or IL-4 (10 ng/ml). A) Total RNA 
was harvested 12 hours after cytokine treatment, quantitated by real-time PCR and normalized to levels of GAPDH mRNA. 
The graph represents five independent experiments performed in triplicate, expressed as mean +/- SEM. B) Conditioned 
medium was collected from cultures after 24 hours incubation with cytokines +/- MK886 at the indicated doses. MMP-3 pro-
tein levels were determined by ELISA. The graph shows data from two different HGF cultures derived from two different 
donors. C) COS-1 cells were transiently transfected with a luciferase reporter construct containing 2300 bp of the human 
MMP-3 5' flanking sequence, along with an SV-β-gal reporter as a control for transfection efficiency. MK886 was added 16 
hours after transfection, and cells were harvested 24 hours later. Shown are data from three independent experiments per-
formed in triplicate, normalized to levels of β-galactosidase, and expressed relative to control, mean +/- SEM. Statistical signifi-
cance was determined using Student's t-test.
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Previous studies with the AP-1 site failed to detect any
changes in DNA binding in cells treated with IL-1 plus IL-
4 as compared to IL-1 alone [34,35]. Use of a larger probe
containing the putative PPRE/AP-1 composite site did
show decreased intensity of retarded bands in the pres-
ence of IL-4 (Figure 2). However there was no change in
the migration of the retarded bands as one would expect
if PPARγ were binding to the site in competition with AP-
1, and a PPARγ specific antibody failed to supershift the
bands. IL-4 has been reported to stimulate expression of
JunB in peripheral blood monocytes from patients with
atopic dermatitis [48]. Since JunB is less transcriptionally
active than c-Jun [49,50], such a shift in the composition
of AP-1 dimers would be expected to decrease transcrip-
tion of at least some AP-1 dependent genes. Use of antis-
era against phosphorylated (active) c-Jun and Jun B
suggest that IL-4 is not interfering with activation of c-Jun,
nor is it changing AP-1 activity by causing the formation
of less active dimers containing JunB. Taken together,
these data demonstrate that IL-4 inhibition of MMP-3
expression cannot be explained by competition for bind-
ing to the AP-1 site or by changes in the composition of
the AP-1 dimer.
Activation of PPARγ has been shown to inhibit cytokine
stimulated gene expression in a number of ways, includ-
ing inhibition of NF-κB and AP-1 activity through compe-
tition for limiting amounts of transcriptional coactivators
[46,47]. Furthermore, IL-4 has been shown to activate
PPARγ by stimulating the production of ligands through
the lipoxygenase pathway [37-39] and in at least one case,
through the production of alternative ligands [39].
Pioglitazone fails to inhibit IL-1 induced MMP-3 Figure 5
Pioglitazone fails to inhibit IL-1 induced MMP-3. HGF cultures were pre-treated with pioglitazone at the indicated doses 
for one hour before addition of IL-1 (10 ng/ml). Total RNA was isolated at 6 hours, quantitated by real-time PCR and normal-
ized to levels of GAPDH. The graph represents data from three independent experiments performed in triplicate, mean +/- 
SEM. Statistical significance was determined by Students T-test, p = 0.025 at 1 µM, 0.06 at 10 µM vs IL-1 alone.
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PPARγ ligand 15dPGJ2 also induces MMP-3 transcription in COS-1 cells Figure 6
PPARγ ligand 15dPGJ2 also induces MMP-3 transcription in COS-1 cells. A) HGF cultures were pre-treated with 
15dPGJ2 at the indicated doses for one hour before addition of IL-1 (10 ng/ml) and/or IL-4 (10 ng/ml). Total RNA was isolated 
at 12 hours, quantitated by real-time PCR and normalized to levels of GAPDH. The graph represents data from six independ-
ent experiments performed in triplicate, mean +/- SEM. B) COS-1 cells were transiently transfected with a luciferase reporter 
construct containing 2300 bp of the human MMP-3 5' flanking sequence, along with an SV-β-gal reporter as a control for trans-
fection efficiency. 15dPGJ2 was added 16 hours after transfection, and cells were harvested 24 hours later. Shown are data 
from three independent experiments performed in triplicate, normalized to levels of β-galactosidase, and expressed relative to 
control, mean +/- SEM. Statistical significance was determined using Student's t-test.
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The fact that IL-4 could still inhibit MMP-3 expression in
the presence of NDGA or MK886 suggests that the mech-
anism of IL-4 inhibition does not require activation of
lipoxygenase enzymes. Super-induction of IL-1 stimulated
MMP-3 expression by NDGA was surprising in light of the
fact that NDGA is known to inhibit AP-1 activity [51] and
it has been shown to inhibit expression of MMP-3 in
response to IL-17 [52]. Since pioglitazone also resulted in
stimulation of MMP-3 expression while inhibiting AP-1
binding (Figures 2, 5), it is clear that other pathways are
more important than AP-1 in this context.
As reported earlier [35], IL-4 failed to inhibit IL-1 induc-
tion of MMP-1. Although NDGA induced MMP-1 over
control levels, it failed to super-induce MMP-1 with IL-1
as it did with MMP-3. These results represent another
addition to a growing list of situations in which these two
genes are not co-ordinately regulated. In one instance,
Otani et al [53] showed induction of MMP-3, but not
MMP-1 in the presence of cycloheximide. They suggested
that cycloheximide might be inducing MMP-3 expression
by preventing translation of a "labile repressor". It is inter-
esting to note as well that the increased transcription of
the MMP-3 promoter construct was observed only with
the construct containing the 5A polymorphism and not in
the construct containing the 6A polymorphism (data not
shown). Since this polymorphic site has been shown to
act as a repressor element in normal fibroblasts [16,54], it
is tempting to speculate that these reagents are affecting
the binding or activity of transcription factor(s) binding
to this site in order to relieve the repression. Further exper-
iments are needed to address these questions.
PPAR antagonist GW9662 fails to reverse the inhibitory effects of IL-4 Figure 7
PPAR antagonist GW9662 fails to reverse the inhibitory effects of IL-4. HGF cultures were pre-treated with 
GW9662 at the indicated doses for one hour before addition of IL-1 (10 ng/ml) and/or IL-4 (10 ng/ml). Total RNA was isolated 
at 12 hours, quantitated by real-time PCR and normalized to levels of GAPDH. The graph represents data from six independ-
ent experiments performed in triplicate, mean +/- SEM. Statistical significance was determined by Students T-test.
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Interactions between the cyclooxygenase, lipoxygenase
and PPAR pathways are overlapping and complex. Arachi-
donic acid is a common substrate for both cyclooxygenase
and lipoxygenase enzymes. Expression of 15- and 5-lipox-
ygenase enzymes is often reciprocal [55,56]. Activation of
PPARγ by troglitazone has been shown to inhibit expres-
sion of 5-lipoxygenase in rheumatoid arthritis synovial
fibroblasts [57], lipoxygenase inhibitors can activate
PPARγ in breast cancer cells [58] and COX-2 expression in
macrophages has been postulated to be regulated by neg-
ative feedback mediated by PPARγ [59].
One potential explanation for the unexpected effects of
NDGA and MK886, therefore, is that inhibition of lipoxy-
genase enzymes leads to an excess of arachidonic acid,
which can then be converted to prostaglandins by
cyclooxygenases. If pioglitazone and/or 15d PGJ2 caused
a down-regulation of 5-lipoxygenase expression and/or
activity, then they too could result in increased levels of
arachidonic acid and increased production of prostaglan-
dins.
This is not straight-forward however, since the effects of
PGE2 on MMP-3 expression are variable, ranging from
induction [60,61], to inhibition [62-64], to no effect
[30,65]. A particularly interesting study by Rowanpura et
al. [66], showed that the effects of PGE2 on IL-1 stimu-
lated expression of MMP-3 differ in HGF derived from
healthy tissue as opposed to HGF derived from patients
with severe periodontitis. In HGF from healthy donors,
PGE2 inhibited the IL-1 induction of MMP-3, whereas in
diseased tissue, it resulted in further stimulation. This dif-
ference was shown to result from a change in PGE2 recep-
tors, from EP2 and EP4 in healthy tissue to predominantly
EP1 in diseased tissue.
Since our HGF were derived from patients with periodon-
titis, it is possible that addition of NDGA, MK886 and/or
pioglitazxone resulted indirectly in increased production
of PGE2, which caused super-induction of MMP-3 as
described by Ruwanpura, et al. [66]. It is important to
note that in previous studies using similarly derived HGF,
addition of exogenous PGE2 failed to abrogate the sup-
pressive effects of IL-4 on MMP-3 expression [35], but the
effects of exogenous PGE2 alone or together with IL-1
were not tested. In the present study, there was some var-
iation in the magnitude of responses, but the responses
themselves were qualitatively consistent among cultures
established from different individuals (n = 7 for NDGA, n
= 5 for MK886, n = 3 for pioglitazone, n = 6 for 15d PGJ2
experiments).
Aside from demonstrating that PPARγ is not involved in
the effects of IL-4 on MMP-3 expression, the failure of
pioglitazone and 15dPGJ2 to inhibit MMP-3 expression
(Figures 5 and 6) was surprising because other studies
have shown inhibition of MMP-3 expression by activators
of PPARγ [40,41]. The most obvious explanation for the
super-induction would be the presence of a PPRE in the
MMP-3 promoter. Computer analysis of the promoter
sequence [Genomatix, [67]] failed to identify any PPRE.
However, a recent study found that of the 73 known func-
tional PPRE, only 2 conformed to the DR1 consensus, and
8% of them had 5 or more mismatches [68]. Therefore,
this possibility cannot be excluded without further study.
The possibility of PPARγ-independent effects of pioglita-
zone and 15dPGJ2 also cannot be ruled out. 15dPGJ2 has
been shown to have several effects independent of PPAR,
including inhibition of NFκB [69]. Pioglitazone has been
shown to up-regulate AMP-activated kinase in rat muscle
and in NIH3T3 cells)[70] and to increase LPS stimulated
production of PGE2 at high doses [71]. Aizawa et al. [72]
showed that pioglitazone increased the IL-1 induced
expression of inducible nitric oxide synthase (iNOS) in
vascular smooth muscle cells (VSMCs) independent of
PPARγ.
Both NDGA and pioglitazone have anti-oxidant proper-
ties which have been linked to their ability to inhibit the
activity of redox sensitive transcription factor NF-κB
[43,73,74]. NF-κB has been implicated in several studies
to be involved in up-regulation of MMP-3 in inflamma-
tion [75-77], but more recent studies have shown that NF-
κB binds to a polymorphic repressor element in the MMP-
3 promoter in competition with zinc-binding protein 89
(ZBP-89) to limit IL-1 induced transcription [54], unpub-
lished]. Further study is needed to determine more pre-
cisely the direct and indirect roles of NF-κB in MMP-3
regulation and how these roles are affected by any altera-
tions in eicosanoid synthesis or actions that might take
place in the context of chronic inflammation.
Conclusion
In summary, these data demonstrate that the ability of IL-
4 to suppress IL-1 induced expression of MMP-3 does not
involve activation of PPARγ and/or lipoxygenase activity
in HGF. However, the fact that lipoxygenase inhibition
and PPARγ activation were both able to super-induce
MMP-3 mRNA suggests that these pathways are involved
in MMP-3 gene regulation. These results also suggest that
treatment with drugs that target these pathways in the
context of chronic inflammation could have some unpre-
dicted effects. Further study is necessary to determine how
these effects are mediated and to what extent they are rel-
evant to the disease process(es).BMC Molecular Biology 2007, 8:12 http://www.biomedcentral.com/1471-2199/8/12
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Methods
Cell culture
Human gingival tissue from patients undergoing perio-
dontal surgery was obtained from Howard M. Sobel,
D.D.S. and Kevan S. Green, D.M.D. of Sobel Periodontal
Associates, P.C. The tissue was processed by enzymatic
dispersion to produce primary cultures. Cells were main-
tained in Eagle's Minimal Essential Medium (EMEM) sup-
plemented with 10% fetal bovine serum and antibiotic/
antimycotic (penicillin, streptomycin, amphotericin;
Gibco BRL, Grand Island, NY). Cells between passages 3
and 5 were used for experiments. COS-1 cells were
obtained from ATCC and maintained as suggested.
RNA isolation and real-time PCR
Cells were serum-deprived for 16 hours in serum-free
EMEM supplemented with 10% ITS (insulin, transferrin,
sodium selenite; Sigma, St. Louis, MO) prior to the addi-
tion of NDGA, MK886, pioglitazone, 15dPGJ2 or
GW9962 (Sigma) in the indicated doses. After one hour
incubation, 10 ng IL-1β/ml (DuPont-Merck Corp., Wilm-
ington, DE) was added, in the presence or absence of 10
ng/ml IL-4 (Gibco BRL, Grand Island, NY). Total RNA was
isolated 6 or 12 hours later using the RNAqueous-4PCR
kit (Ambion, Austin, TX) according to manufacture's
instructions and reverse transcribed into cDNA using the
High Capacity cDNA Archive Kit (Applied Biosystem, Fos-
ter City, CA) and Thermal Cycler Genius. Real Time PCR
reactions were consisted of 2.5 µl of cDNA, 12.5 µl of Taq-
man Universal PCR master mix (Applied Biosystem), 8.75
µl H2O and 1.25 µl probes (stromylsin-MMP-3, colla-
genase I-MMP-1, Glyceraldehyde-3-Phosphate Dehydro-
genase-GAPDH; Applied Biosystem) or 2 µl of cDNA, 6.8
µl of H2O, 10 µl of the Premix Ex Taq™ (master mix and
0.4 µl ROX Reference Dye; TAKARA, Madison, WI) and
0.8 µl probes. Real Time PCR analysis was done using the
Applied Biosystem 7500 Real Time PCR system. Reactions
were done in triplicate and results were normalized to
GAPDH.
Nuclear extract isolation and gelshift assays
Nuclear extracts were isolated according to the method of
Schreiber et al. [78] and quantified in mini-Bradford
assays (Pierce, Rockford, IL). Synthetic oligonucleotides
corresponding to the putative composite PPRE/AP-1 site
(5' GAAAGCAAGGTGAGTCAAGCTG 3') [45] were
labelled by T4 polynucleotide kinase in the presence of
γ32P-ATP. Binding reactions contained 5 µg protein, 20
mM Hepes-OH pH 7, 50 mM NaCl, 0.2 M EDTA, 5% glyc-
erol, 4 µg dIdC and 10,000 cpm probe.
Western Blotting
Fifteen µg nuclear extract were separated on 10% SDS-
polyacrylamide gels. Proteins were transferred to Immo-
bilon-P Transfer Membrane (Millipore) and the mem-
brane was blocked overnight with Super Block blocking
buffer (Pierce). The blot was then incubated with anti-
PPAR-γ antibody (Santa Cruz) diluted 1:1000 in Super
Block for one hour at room temperature. After washing
three times in TBST (20 mM Tris-HCl pH 7.5, 150 mM
NaCl, 0.5% Tween 20), the blots were incubated with a
goat anti-rabbit secondary antibody conjugated to horse-
radish peroxidase (Pierce) for one hour. After three more
washes in TBST, the blot was incubated with SuperSignal
West Pico Chemiluminescent Substrate (Pierce) and
exposed to X-ray film.
Transient transfection
A luciferase reporter construct containing 2300 bp of the
MMP-3 5' flanking region and the 5T promoter polymor-
phism has been described previously [79]. Transient
transfections were performed in triplicate using Lipo-
fectamine Plus (GibcoBRL), with SV-βgal as a control for
transfection efficiency. Cells were harvested 36 hours
later.
Determination of MMP-3 protein levels
MP-3 protein levels were quantitated by ELISA (Calbio-
chem, Darmstadt, Germany) in conditioned media of
human gingival fibroblasts (HGF) that were untreated,
treated with 10 ng IL-1/ml alone or treated with both 10
ng IL-1/ml and 0.1, 1.0 or 10 µM MK886 for 24 hours.
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